These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

458 related articles for article (PubMed ID: 26820289)

  • 21. Prospects of Treating Tenosynovial Giant Cell Tumor through Pexidartinib: A Review.
    Alsayadi YMMA; Chawla PA
    Anticancer Agents Med Chem; 2021; 21(12):1510-1519. PubMed ID: 33143617
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pexidartinib for the treatment of adult symptomatic patients with tenosynovial giant cell tumors.
    Baldi GG; Gronchi A; Stacchiotti S
    Expert Rev Clin Pharmacol; 2020 Jun; 13(6):571-576. PubMed ID: 32478598
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Does CSF1 overexpression or rearrangement influence biological behaviour in tenosynovial giant cell tumours of the knee?
    Mastboom MJL; Hoek DM; Bovée JVMG; van de Sande MAJ; Szuhai K
    Histopathology; 2019 Jan; 74(2):332-340. PubMed ID: 30152874
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tenosynovial giant cell tumor.
    Kager M; Kager R; Fałek P; Fałek A; Szczypiór G; Niemunis-Sawicka J; Rzepecka-Wejs L; Starosławska E; Burdan F
    Folia Med Cracov; 2022; 62(2):93-107. PubMed ID: 36256897
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long term term follow-up of tyrosine kinase inhibitors treatments in inoperable or relapsing diffuse type tenosynovial giant cell tumors (dTGCT).
    Brahmi M; Cassier P; Dufresne A; Chabaud S; Karanian M; Meurgey A; Bouhamama A; Gouin F; Vaz G; Garret J; Sunyach MP; Dupré A; Marec-Berard P; Corradini N; Perol D; Ray-Coquard I; Blay JY
    PLoS One; 2020; 15(5):e0233046. PubMed ID: 32433669
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term outcome of the treatment of high-risk tenosynovial giant cell tumor/pigmented villonodular synovitis with radiotherapy and surgery.
    Griffin AM; Ferguson PC; Catton CN; Chung PW; White LM; Wunder JS; Bell RS; O'Sullivan B
    Cancer; 2012 Oct; 118(19):4901-9. PubMed ID: 22281719
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term clinical activity, safety and patient-reported quality of life for emactuzumab-treated patients with diffuse-type tenosynovial giant-cell tumour.
    Cassier PA; Italiano A; Gomez-Roca C; Le Tourneau C; Toulmonde M; D'Angelo SP; Weber K; Loirat D; Jacob W; Jegg AM; Michielin F; Christen R; Watson C; Cannarile M; Klaman I; Abiraj K; Ries CH; Weisser M; Rüttinger D; Blay JY; Delord JP
    Eur J Cancer; 2020 Dec; 141():162-170. PubMed ID: 33161240
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Multimodal management of tenosynovial giant cell tumors (TGCT) in the landscape of new druggable targets.
    van der Heijden L; Spierenburg G; Kendal JK; Bernthal NM; van de Sande MAJ
    J Surg Oncol; 2023 Sep; 128(3):478-488. PubMed ID: 37537982
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tenosynovial giant cell tumors (TGCT): molecular biology, drug targets and non-surgical pharmacological approaches.
    Spierenburg G; van der Heijden L; van Langevelde K; Szuhai K; Bovée JVGM; van de Sande MAJ; Gelderblom H
    Expert Opin Ther Targets; 2022 Apr; 26(4):333-345. PubMed ID: 35443852
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pexidartinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor: safety and efficacy.
    Palmerini E; Longhi A; Donati DM; Staals EL
    Expert Rev Anticancer Ther; 2020 Jun; 20(6):441-445. PubMed ID: 32297819
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tenosynovial giant cell tumour/pigmented villonodular synovitis: outcome of 294 patients before the era of kinase inhibitors.
    Palmerini E; Staals EL; Maki RG; Pengo S; Cioffi A; Gambarotti M; Picci P; Daolio PA; Parafioriti A; Morris C; Antonescu CR; Gronchi A; Casali PG; Donati DM; Ferrari S; Stacchiotti S
    Eur J Cancer; 2015 Jan; 51(2):210-7. PubMed ID: 25465190
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Detection of CSF1 rearrangements deleting the 3' UTR in tenosynovial giant cell tumors.
    Ho J; Peters T; Dickson BC; Swanson D; Fernandez A; Frova-Seguin A; Valentin MA; Schramm U; Sultan M; Nielsen TO; Demicco EG
    Genes Chromosomes Cancer; 2020 Feb; 59(2):96-105. PubMed ID: 31469468
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The growing problem of benign connective tissue tumours.
    Thomas DM
    Lancet Oncol; 2015 Aug; 16(8):879-80. PubMed ID: 26179199
    [No Abstract]   [Full Text] [Related]  

  • 34. Giant cell tumor of tendon sheath, tenosynovial giant cell tumor, and pigmented villonodular synovitis: defining the presentation, surgical therapy and recurrence.
    Martin RC; Osborne DL; Edwards MJ; Wrightson W; McMasters KM
    Oncol Rep; 2000; 7(2):413-9. PubMed ID: 10671695
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Updates on the Treatment of Tenosynovial Giant Cell Tumor.
    Chan AS; Katiyar V; Dy P; Singh V
    Hematol Oncol Stem Cell Ther; 2023 May; 16(4):307-315. PubMed ID: 37363972
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Real-world drug utilization and treatment patterns in patients with tenosynovial giant cell tumors in the USA.
    Dharmani C; Fofah O; Wang E; Salas M; Wooddell M; Tu N; Tse J; Near A; Tinoco G
    Future Oncol; 2024; 20(16):1079-1097. PubMed ID: 38380590
    [No Abstract]   [Full Text] [Related]  

  • 37. Tenosynovial giant cell tumor: case report and review.
    Lucas DR
    Arch Pathol Lab Med; 2012 Aug; 136(8):901-6. PubMed ID: 22849738
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Expression of colony-stimulating factor 1 is associated with occurrence of osteochondral change in pigmented villonodular synovitis.
    Ota T; Urakawa H; Kozawa E; Ikuta K; Hamada S; Tsukushi S; Shimoyama Y; Ishiguro N; Nishida Y
    Tumour Biol; 2015 Jul; 36(7):5361-7. PubMed ID: 25854167
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Patient-reported Symptoms of Tenosynovial Giant Cell Tumors.
    Gelhorn HL; Tong S; McQuarrie K; Vernon C; Hanlon J; Maclaine G; Lenderking W; Ye X; Speck RM; Lackman RD; Bukata SV; Healey JH; Keedy VL; Anthony SP; Wagner AJ; Von Hoff DD; Singh AS; Becerra CR; Hsu HH; Lin PS; Tap WD
    Clin Ther; 2016 Apr; 38(4):778-93. PubMed ID: 27041409
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CSF-1R Inhibitor Development: Current Clinical Status.
    Peyraud F; Cousin S; Italiano A
    Curr Oncol Rep; 2017 Sep; 19(11):70. PubMed ID: 28875266
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.